Warning Letter Close-Outs – November 2022
The US FDA released three device-related close-out letters in November, all of which related to premarket conduct.
You may also be interested in...
Competitive value propositions are a must in 2023 to win guarded consumers’ business. Companies that effectively address mental health and wellbeing needs and appeal to consumers through sustainability initiatives could have an edge in the recessionary environment, experts suggest. Meanwhile, there are concerns about small cosmetics companies and the availability of resources to help them comply with "modernized" federal regulations.
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.